Scribe Therapeutics surges in New York debut after upsized $128.7 million IPO

Scribe Therapeutics

24/07/2026 19:27

Updates
** Gene-editing startup Scribe Therapeutics' SCTX.O shares surge as much as 69.9% in New York debut 
** Stock opened at $25 apiece vs $15 IPO price 
** Alameda, California-based SCTX sold ~8.6 million shares in upsized IPO to raise $128.7 million 
** SCTX, which is building a portfolio of genetic medicines for cardiometabolic diseases, had earlier marketed 7.2 million shares at between $13 and $15 apiece 
** Its lead candidate, STX-1150, is being developed to lower low-density lipoprotein cholesterol levels, a key driver of cardiovascular risk 
** Every 40 seconds, someone in the U.S. suffers a heart attack, and each year, heart disease costs the nation more than $400 billion, according to the American Heart Association
** Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities acted as joint book-running managers for offering

 (Reporting by Arasu Kannagi Basil in Bengaluru)
 ((ArasuKannagi.Basil@thomsonreuters.com;))